Posted by Michael Wonder on 31 May 2022
TG Therapeutics announces FDA extension of BLA PDUFA date for ublituximab to treat patients with RMS
31 May 2022 - New PDUFA goal date of 28 December 2022.
TG Therapeutics today announced that the U.S. FDA has extended the Prescription Drug User Fee Act goal date to 28 December 2022, for the biologics license application for ublituximab as a treatment for patients with relapsing forms of multiple sclerosis.
